Neogen Valuation
Is NEOG * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NEOG * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NEOG * (MX$377.71) is trading below our estimate of fair value (MX$923.81)
Significantly Below Fair Value: NEOG * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NEOG *?
Other financial metrics that can be useful for relative valuation.
What is NEOG *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$3.47b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 4.5x |
Enterprise Value/EBITDA | 18.5x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does NEOG *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 4.2x | ||
7747 Asahi Intecc | 5.7x | 8.3% | JP¥579.9b |
ICUI ICU Medical | 1.1x | 2.5% | US$2.5b |
HAE Haemonetics | 3.4x | 8.1% | US$4.5b |
603658 Autobio Diagnostics | 6.7x | 16.5% | CN¥29.9b |
NEOG * Neogen | 3.8x | 5.9% | Mex$3.5b |
Price-To-Sales vs Peers: NEOG * is good value based on its Price-To-Sales Ratio (3.8x) compared to the peer average (8.9x).
Price to Earnings Ratio vs Industry
How does NEOG *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Sales vs Industry: NEOG * is expensive based on its Price-To-Sales Ratio (3.8x) compared to the Global Medical Equipment industry average (3.5x).
Price to Sales Ratio vs Fair Ratio
What is NEOG *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 3.8x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate NEOG *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.